Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Team-based learning in pharmacy education.

Ofstad W, Brunner LJ.

Am J Pharm Educ. 2013 May 13;77(4):70. doi: 10.5688/ajpe77470. Review.

2.

Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome.

Yan AT, Yan RT, Tan M, Huynh T, Soghrati K, Brunner LJ, DeYoung P, Fitchett DH, Langer A, Goodman SG; Canadian ACS Registries Investigators.

Am Heart J. 2007 Dec;154(6):1108-15. Epub 2007 Sep 14.

PMID:
18035083
3.

Impact of transgene expression on drug metabolism following systemic adenoviral vector administration.

Callahan SM, Boquet MP, Ming X, Brunner LJ, Croyle MA.

J Gene Med. 2006 May;8(5):566-76.

PMID:
16508909
4.

Considerations for use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450.

Callahan SM, Ming X, Lu SK, Brunner LJ, Croyle MA.

J Pharmacol Exp Ther. 2005 Feb;312(2):492-501. Epub 2004 Oct 20.

5.

Cyclosporine and bromocriptine-induced suppressions of CYP3A1/2 and CYP2C11 are not mediated by prolactin.

Lu SK, Callahan SM, Jin R, Brunner LJ.

Eur J Pharmacol. 2004 Oct 6;501(1-3):215-24.

PMID:
15464081
6.

Metabolic interaction between cyclosporine and sirolimus.

Bai S, Stepkowski SM, Kahan BD, Brunner LJ.

Transplantation. 2004 May 27;77(10):1507-12.

PMID:
15239612
7.
8.

The effect of lipoprotein-associated cyclosporine on drug metabolism and toxicity in rats.

Kim T, Lu SK, Brunner LJ.

PDA J Pharm Sci Technol. 2003 Nov-Dec;57(6):410-24.

PMID:
14765557
9.

PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum.

Croyle MA, Callahan SM, Auricchio A, Schumer G, Linse KD, Wilson JM, Brunner LJ, Kobinger GP.

J Virol. 2004 Jan;78(2):912-21.

10.

Effect of high-density lipoprotein associated cyclosporine on hepatic metabolism and renal function.

Kim T, Callahan SM, Wasan KM, Brunner LJ.

PDA J Pharm Sci Technol. 2003 Sep-Oct;57(5):341-50.

PMID:
14677627
11.

Effect of sodium alterations on hepatic cytochrome P450 3A2 and 2C11 and renal function in rats.

Liu J, Callahan SM, Brunner LJ.

Drug Dev Ind Pharm. 2003 Aug;29(7):767-75.

PMID:
12906334
12.
13.

Bayeswatch: an overview of Bayesian statistics.

Austin PC, Brunner LJ, Hux JE.

J Eval Clin Pract. 2002 May;8(2):277-86.

PMID:
12060417
14.

Effect of gender and estrous cycle on the pharmacokinetics of ethanol in the rat brain.

Robinson DL, Brunner LJ, Gonzales RA.

Alcohol Clin Exp Res. 2002 Feb;26(2):165-72.

PMID:
11964555
15.

Altered cytochrome P450 and P-glycoprotein levels in rats during simulated weightlessness.

Lu SK, Bai S, Javeri K, Brunner LJ.

Aviat Space Environ Med. 2002 Feb;73(2):112-8.

PMID:
11846179
16.

In vivo induction of hepatic p-glycoprotein by cyclosporine in the rat.

Bai S, Liu J, Lu SK, Brunner LJ.

Res Commun Mol Pathol Pharmacol. 2001 Jul;109(1-2):103-14.

PMID:
11458978
17.

Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat1.

Bai S, Brunner LJ, Stepkowski SM, Napoli KL, Kahan BD.

Transplantation. 2001 Jun 15;71(11):1585-92.

PMID:
11435969
18.

Chronic cyclosporine administration induces renal P-glycoprotein in rats.

Liu J, Brunner LJ.

Eur J Pharmacol. 2001 Apr 20;418(1-2):127-32.

PMID:
11334874
19.

Effect of grapefruit juice on cyclosporin A pharmacokinetics in pediatric renal transplant patients.

Brunner LJ, Pai KS, Munar MY, Lande MB, Olyaei AJ, Mowry JA.

Pediatr Transplant. 2000 Nov;4(4):313-21.

PMID:
11079273
20.

Effect of simulated weightlessness on phase II drug metabolism in the rat.

Brunner LJ, Bai S, Abdus-Salaam H.

Aviat Space Environ Med. 2000 Sep;71(9):899-903.

PMID:
11001342
21.
22.

Effect of dietary oil intake on hepatic cytochrome P450 activity in the rat.

Brunner LJ, Bai S.

J Pharm Sci. 2000 Aug;89(8):1022-7.

PMID:
10906725
23.

Effect of dose on cyclosporine-induced suppression of hepatic cytochrome P450 3A2 and 2C11.

Brunner LJ, Werner U, Gravenall CE.

Eur J Pharm Biopharm. 2000 Mar;49(2):129-35.

PMID:
10704895
24.

Simple and rapid assay for acetaminophen and conjugated metabolites in low-volume serum samples.

Brunner LJ, Bai S.

J Chromatogr B Biomed Sci Appl. 1999 Sep 24;732(2):323-9.

PMID:
10517354
25.

Gender differences in blood levels, but not brain levels, of ethanol in rats.

Crippens D, White ML, George MA, Jaworski JN, Brunner LJ, Lancaster FE, Gonzales RA.

Alcohol Clin Exp Res. 1999 Mar;23(3):414-20.

PMID:
10195812
26.

Capillary electrophoresis for therapeutic drug monitoring.

Brunner LJ, DiPiro JT.

Electrophoresis. 1998 Nov;19(16-17):2848-55. Review.

PMID:
9870379
27.

Cyclosporine suppresses rat hepatic cytochrome P450 in a time-dependent manner.

Brunner LJ, Bennett WM, Koop DR.

Kidney Int. 1998 Jul;54(1):216-23.

28.

Interaction between cyclosporine and grapefruit juice requires long-term ingestion in stable renal transplant recipients.

Brunner LJ, Munar MY, Vallian J, Wolfson M, Stennett DJ, Meyer MM, Bennett WM.

Pharmacotherapy. 1998 Jan-Feb;18(1):23-9.

PMID:
9469677
29.

Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine.

Wasan KM, Pritchard PH, Ramaswamy M, Wong W, Donnachie EM, Brunner LJ.

Pharm Res. 1997 Nov;14(11):1613-20.

PMID:
9434283
30.

Selective suppression of rat hepatic microsomal activity during chronic cyclosporine nephrotoxicity.

Brunner LJ, Bennett WM, Koop DR.

J Pharmacol Exp Ther. 1996 Jun;277(3):1710-8.

PMID:
8667242
31.

Antipyrine pharmacokinetics in the tail-suspended rat model.

Brunner LJ, DiPiro JT, Feldman S.

J Pharmacol Exp Ther. 1995 Jul;274(1):345-52.

PMID:
7616419
32.

High-performance capillary electrophoresis in the pharmaceutical sciences.

Brunner LJ, DiPiro JT, Feldman S.

Pharmacotherapy. 1995 Jan-Feb;15(1):1-22. Review.

PMID:
7739940
33.

Metabolic cage isolation reduces antipyrine clearance in rats.

Brunner LJ, Dipiro JT, Feldman S.

J Pharm Pharmacol. 1994 Jul;46(7):581-4.

PMID:
7996387
34.

Small animal model of weightlessness for pharmacokinetic evaluation.

Feldman S, Brunner LJ.

J Clin Pharmacol. 1994 Jun;34(6):677-83. Review.

PMID:
8083400
35.

Reconstituted high density lipoprotein inhibits physiologic and tumor necrosis factor alpha responses to lipopolysaccharide in rabbits.

Cué JI, DiPiro JT, Brunner LJ, Doran JE, Blankenship ME, Mansberger AR, Hawkins ML.

Arch Surg. 1994 Feb;129(2):193-7.

PMID:
8304830
36.

Serum antipyrine concentrations determined by micellar electrokinetic capillary chromatography.

Brunner LJ, DiPiro JT, Feldman S.

J Chromatogr. 1993 Dec 8;622(1):98-102.

PMID:
8120120
37.

Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation.

Yau JC, LeMaistre CF, Andersson BS, Huan SD, Wallerstein RO, Woo SY, Spitzer G, Spinolo JA, Spencer V, Brunner LJ, et al.

Am J Hematol. 1992 Sep;41(1):40-4.

PMID:
1503097
38.

Pharmacokinetics of cyclosporine in bone marrow transplantation: longitudinal characterization of drug in lipoprotein fractions.

Luke DR, Brunner LJ, Lopez-Berestein G, Yau JC.

J Pharm Sci. 1992 Mar;81(3):208-11.

PMID:
1640354
39.

An effective acute graft-vs.-host disease prophylaxis with minidose methotrexate, cyclosporine, and single-dose methylprednisolone.

Yau JC, Dimopoulos MA, Huan SD, Spencer V, Woo SY, Spitzer G, Brunner LJ, Wallerstein RO, Deisseroth AB, Andersson BS, et al.

Am J Hematol. 1991 Dec;38(4):288-92.

PMID:
1746537
40.

Attenuation of amphotericin-B nephrotoxicity in the candidiasis rat model.

Luke DR, Wasan KM, Verani RR, Brunner LJ, Berens KL, Vadiei K, Lopez-Berestein G.

Nephron. 1991;59(1):139-44.

PMID:
1944727
41.

Therapeutic drug monitoring of cyclosporine-lipoprotein levels.

Yau JC, Brunner LJ, Lopez-Berestein G, LeMaistre CF, Luke DR.

Pharmacotherapy. 1991;11(4):291-5.

PMID:
1923909
42.

Influence of lovastatin on the pharmacokinetics, toxicity and immunologic response of cyclosporine in the obese Zucker rat.

Berens KL, Vadiei K, Brunner LJ, Wasan KM, Luke DR.

Biopharm Drug Dispos. 1990 Apr;11(3):197-206.

PMID:
2328306
43.

Single-dose cyclosporine pharmacokinetics in various biological fluids of patients receiving allogeneic marrow transplantation.

Brunner LJ, Luke DR, Lautersztain J, Williams LA, LeMaistre CF, Yau JC.

Ther Drug Monit. 1990 Mar;12(2):134-8.

PMID:
2315970
44.

Bioavailability assessment of cyclosporine in the rat. Influence of route of administration.

Luke DR, Brunner LJ, Vadiei K.

Drug Metab Dispos. 1990 Mar-Apr;18(2):158-62.

PMID:
1971566
45.

Increased sensitivity in a radioimmunoassay for measuring cyclosporine in lipoprotein fractions.

Brunner LJ, Yau JC, Lautersztain J, Luke DR.

Clin Chem. 1990 Feb;36(2):329-31.

46.

Impact of time and feeding habits on lipid levels in Zucker obese rats.

Brunner LJ, Wasan KM, Vadiei K, Berens KL, Luke DR.

Prog Clin Biol Res. 1990;341B:195-201.

PMID:
2217311
47.

Cyclosporine pharmacokinetics and effect in the type I diabetic rat model.

Brunner LJ, Iyer LV, Vadiei K, Weaver WV, Luke DR.

Eur J Drug Metab Pharmacokinet. 1989 Oct-Dec;14(4):287-92.

PMID:
2699289
48.

Effects of pentoxifylline in experimental acute renal failure.

Vadiei K, Brunner LJ, Luke DR.

Kidney Int. 1989 Sep;36(3):466-70.

49.

Circadian assessment of lipids in the hyperphagic obese rat compared with lean litter-mates.

Wasan KM, Brunner LJ, Berens KL, Meltzer AA, Luke DR.

Chronobiol Int. 1989;6(3):223-8.

PMID:
2680123
50.

Cilastatin-insulin interaction in the rat.

Tompkins GC, Brunner LJ, Luke DR.

Drug Metab Dispos. 1989 Jan-Feb;17(1):54-7.

PMID:
2566470

Supplemental Content

Loading ...
Support Center